Druglikeness

Druglikeness is a qualitative concept used in drug design for how "druglike" a substance is with respect to factors like bioavailability. It is estimated from the molecular structure before the substance is even synthesized and tested. A druglike molecule has properties such as:

• Solubility in both water and fat, as an orally administered drug needs to pass through the intestinal lining after it is consumed, be carried in aqueous blood and penetrate the lipid-based cell membrane to reach the inside of a cell. A model compound for the lipophilic cellular membrane is 1-octanol (a lipophilic hydrocarbon), so the logarithm of the octanol/water partition coefficient, known as LogP, is used to predict the solubility of a potential oral drug. This coefficient can be experimentally measured or predicted computationally, in which case it is sometimes called "cLogP".
• Potency at the biological target. High potency (high value of pIC₅₀) is a desirable attribute in drug candidates, as it reduces the risk of non-specific, off-target pharmacology at a given concentration. When associated with low clearance, high potency also allows for low total dose, which lowers the risk of idiosyncratic drug reactions.^[1][2]
• Several scoring methods can be used to express druglikeness as a function of potency and physicochemical properties, for example ligand efficiency and lipophilic efficiency.
• Since the drug is transported in aqueous media like blood and intracellular fluid, it has to be sufficiently water-soluble in the absolute sense (i.e. must have a minimum chemical solubility in order to be effective). Solubility in water can be estimated from the number of hydrogen bond donors vs. alkyl sidechains in the molecule. Low water solubility translates to slow absorption and action. Too many hydrogen bond donors, on the other hand, lead to low fat solubility, so that the drug cannot penetrate the cell membrane to reach the inside of the cell.
• Molecular weight: The smaller the better, because diffusion is directly affected. The great majority of drugs on the market have molecular weights between 200 and 600 Daltons, and particularly <500;^[3][4] they belong to the group of small molecules.
• Substructures that have known chemical or pharmacological properties. For example, alkylnitro compounds tend to be irritants, and Michael acceptors, such as enones, are alkylating agents and thus potentially mutagenic and carcinogenic.^[5]

A traditional method to evaluate druglikeness is to check compliance of Lipinski's Rule of Five, which covers the numbers of hydrophilic groups, molecular weight and hydrophobicity.

Based on one definition, a drug-like molecule has a logarithm of partition coefficient (log P) between -0.4 and 5.6, molecular weight 160-480 g/mol, molar refractivity of 40-130, which is related to the volume and molecular weight of the molecule and has 20-70 atoms.^[6]

Also, other factors such as substructures with known toxic, mutagenic or teratogenic properties affect the usefulness of a designed molecule. In fact, several poisons have a good druglikeness. Natural toxins are used in pharmacological research to find out their mechanism of action, and if it could be exploited for beneficial purposes.

Druglikeness indices are inherently limited tools. Druglikeness can be estimated for any molecule, and does not evaluate the actual specific effect that the drug achieves (biological activity). Simple rules are not always accurate and may unnecessarily limit the chemical space to search: many best-selling drugs have features that cause them to score low on various druglikeness indices.^[7] Furthermore, first-pass metabolism, which is biochemically selective, can destroy the pharmacological activity of a compound despite good druglikeness.

Druglikeness is not relevant for most biologics, since they are usually proteins that need to be injected, because proteins are digested if eaten.

See also

• Lipinski's rule of five (RO5)
• Fragment-based lead discovery (FBLD)

References

1. Uetrecht J (January 2001). "Prediction of a new drug's potential to cause idiosyncratic reactions". Current Opinion in Drug Discovery & Development 4 (1): 55–9. PMID 11727323.
2. Uetrecht J (January 2008). "Idiosyncratic drug reactions: past, present, and future". Chem. Res. Toxicol. 21 (1): 84–92. doi:10.1021/tx700186p. PMID 18052104.
3. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (March 2001). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Adv. Drug Deliv. Rev. 46 (1-3): 3–26. doi:10.1016/S0169-409X(00)00129-0. PMID 11259830.
4. Duffy FJ, Devocelle M, Shields DC (2015). "Computational approaches to developing short cyclic peptide modulators of protein-protein interactions". In Zhou P, Huang J. METHODS IN MOLECULAR BIOLOGY. Computational Peptidology. New York: Humana Press. pp. 250–1. doi:10.1007/978-1-4939-2285-7_11. ISBN 978-1-4939-2284-0. PMID 25555728.
5. Smith GF (February 2011). "Designing drugs to avoid toxicity". Prog. Med. Chem. 50 (1): 1–47. doi:10.1016/B978-0-12-381290-2.00001-X. PMID 21315927.
6. Ghose AK, Viswanadhan VN, Wendoloski JJ (January 1999). "A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases". J Comb Chem 1 (1): 55–68. doi:10.1021/cc9800071. PMID 10746014.
7. http://pipeline.corante.com/archives/2012/03/26/whats_the_ugliest_drug_or_the_ugliest_drug_candidate.php

External links

• OSIRIS Property Explorer: Prediction of druglikeness
• molinspiration free drug-likeness and bioactivity calculator